National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Enzalutamide (Xtandi®) is indicated for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).

 

NCPE Assessment Process Complete
Rapid review commissioned 18/12/2018
Rapid review completed 06/02/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of enzalutamide in combination with ADT compared with the current standard of care